Conventional treatments for ankylosing spondylitis

Annals of the Rheumatic Diseases

Volumn 61, Issue SUPPL. 3, 2002, Pages

  Dougados, Maxime ^a,b   Dijkmans, B ^c   Khan, M ^d   Maksymowych, W ^e   Van der Linden, Sj ^f   Brandt, J ^g  

^a Clinique de Rhumatologie Hôpital Cochin ^*  (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; GOLD; IBUPROFEN; KETOPROFEN; MELOXICAM; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PHENYLBUTAZONE; PIROXICAM; PROSTAGLANDIN SYNTHASE; RISEDRONIC ACID; ROFECOXIB; SALAZOSULFAPYRIDINE; XIMOPROFEN;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ANKYLOSING SPONDYLITIS; ANOREXIA; BLOOD DISEASE; BONE MARROW TOXICITY; BONE PAIN; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOXICITY; DYSPEPSIA; EPIGASTRIC PAIN; FLATULENCE; GASTROINTESTINAL TOXICITY; HEADACHE; HEARTBURN; HIP DISEASE; HUMAN; HYPOCALCEMIA; INJECTION PAIN; INTESTINE OBSTRUCTION; LEUKOPENIA; LIVER TOXICITY; LYMPHOCYTOPENIA; MALAISE; MEGALOBLASTIC ANEMIA; NAUSEA; NEUTROPENIA; PALLIATIVE THERAPY; PATHOGENESIS; PATIENT EDUCATION; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; RISK ASSESSMENT; SACCHAROMYCES; SIDE EFFECT; SPERMATOZOON ABNORMALITY; SPINE FRACTURE; SPINE MALFORMATION; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; VERTIGO; VOMITING;

EID: 0036892787     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (76)

1. Dougados M. Treatment of spondyloarthropathies. Recent advances and prospects in 2001. Joint Bone Spine 2001;68:557-63.
2. Dougados M, Revel M, Khan MA. Spondyloarthropathy treatment: Progress in medical therapy. Baillieres Clin Rheumatol 1998;12:717-36.
3. Dougados M, Caporal R, Doury P, Thiesce A, Pattin S, Laffez B, et al. A double blind cross over placebo controlled trial of ximoprofen in ankylosing spondylitis. J Rheumatol 1989;16:1167-9.
4. Dougados M, Behier JM, Jolchine I, Calin A, van der Heijde D, Olivier I, et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: A six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001;44:180-5.
5. Dougados M, Nguyen M, Caporal R, Legeais J, Bouxin-Sauzet A, Pellegri-Guegnault B, et al. Ximoprofen in ankylosing spondylitis. Scand J Rheumatol 1994;23:243-8.
6. Calin A, Grahame R. Double-blind crossover trial of flurbiprofen and phenylbutazone in ankylosing spondylitis. BMJ 1974;4:496-9.
7. Tannenbaum H, De Coteau WE, Esdaile JM. A double blind multicentre trial comparing piroxicam and indomethacin in ankylosing spondylitis with long-term follow-up. Curr Ther Res 1984;36:425-35.
8. Sturrock RD, Hart FD. Double-blind crossover comparison of indomethacin, flurbiprofen and placebo in ankylosing spondylitis. Ann Rheum Dis 1974;33:129-31.
9. Amor B, Dougados M, Listrat V, Menkes CJ, Dubost JJ, Roux H, et al. Evaluation des critères de spondylarthropathies d'Amor et de l'European Spondylarthropathy Study Group (ESSG). Une etude transversale de 2228 patients. Ann Med Interne (Paris) 1991;142:85-9.
10. Moreland LW, Russell AS, Paulus HE. Management of rheumatoid arthritis: The historical context. J Rheumatol 2001;28:1431-52.
11. Coles LS, Fries JF, Kraines RG, Roth SH. From experiment to experience: Side effects of nonsteroidal anti-inflammatory drugs. Am J Med 1983;74:820-8.
12. Paulus HE. FDA arthritis advisory committee: Serious gastrointestinal toxicity of nonsteroidal antiinflammatory drugs, etc. Arthritis Rheum 1988;31:1450-1.
13. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995;123:241-9.
14. Rostom A, Wells G, Tugwell P, Welch V, Dube C, McGowon J. Prevention of NSAID-induced gastroduodenal ulcers (Cochrane review). In: The Cochrane Library. Oxford:Update Software, 2001:Issue 3.
15. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial. JAMA 1999;282:1921-8.
16. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. JAMA 2000;284:1247-55.
17. Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum 2000;43:370-7.
18. Langmon MJ, Jensen DM, Watson DJ, Harper SE, Zhao P-L, Quan H, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-33.
19. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selected COX-2 inhibitors. JAMA 2001;286:954-9.
20. Peterson WL, Cryer B. COX-1-sparing NSAIDs - Is the enthusiasm justified? JAMA 1999;282:1961-3.
21. Amor B, Dougados M, Mijiyawa M. Criteria of the classification of spondyloarthropathies. Rev Rhum Mal Osteoartic 1990;57:85-9.
22. van der Heijde D, Bellamy N, Calin A, Dougados M, Khan MA, van der Linden S. Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol 1997;24:2225-9.
23. van der Heijde D, Calin A, Dougados M, Khan MA, van der Linden S, Bellamy N. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol 1999;26:951-4.
24. Anderson JJ. Baron G, van der Heijde D, Felston DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
25. Dougados M, Gueguen A, Nakache JP, Velicitat P, Veys EM, Zeidler H, et al. Ankylosing spondylitis: What is the optimum duration of a clinical study? A one year versus a six week nonsteroidal anti-inflammatory drug trial. Rheumatology (Oxford) 1999;38:235-44.
26. Laasila K, Leirisalo-Repo M. Side effects of sulphasalazine in patients with rheumatic diseases or inflammatory bowel disease. Scand J Rheumatol 1994;23:338-40.
27. Ferraz MB, Tugwell P, Goldsmith CH, Atra E. Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 1990;17:1482-6.
28. Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Zeidler H, et al. Sulfasalazine in the treatment of spondyloarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995;38:618-27.
29. Clegg DO, Reda DJ, Weisman MH, Blackburn WD, Cush JJ, Cannon GW, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis: A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2004-12.
30. Clegg DO, Reda DJ, Adbellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthropathies: A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1999;42:2325-9.
31. Hanauer SB, Stathopoulos G. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Saf 1991;6:192-219.
32. Birnie GG, McLeod TIF, Watkinson G. Incidence of sulphasalozine-induced male infertility. Gut 1981;22:452-5.
33. Neumann VC, Taggert AJ, Le Gallez P, Astbury C, Hill J, Bird HA. A study to determine the active moiety of sulfasalazine in rheumatoid arthritis. J Rheumatol 1986;13:285-7.
34. Azad Khan AD, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;ii:889-92.
35. Taggart A, Gardiner P, McEvoy F, Hopkins R, Bird H. Which is the active moiety in ankylosing spondylitis? A randomized, controlled study. Arthritis Rheum 1996;39:1400-5.
36. Thomson GT, Thomson BR, Thomson KS, Ducharme JS. Clinical efficacy of mesalamine in the treatment of spondyloarthropathies. J Rheumatol 2000;27:714-18.
37. Dekker-Saeys BJ, Dijkmanns BA, Tytgat GN. Treatment of spondyloarthropathy with 5-aminosalycylic acid (mesalazine): An open trial. J Rheumatol 2000;27:723-6.
38. Van Denderen JC, Van der Horst-Bruinsma IC, Bezemer PD, Dijkmans BAC. Efficacy and safety of mesalazine (Salfofalk) in patients with ankylosing spondylitis: An open study in 20 patients. J Rheumatol 2002 (submitted).
39. Schattenkirchner M. Indications and contraindications for systemic gold therapy. Wien Klin Wochenschr 1984;156(suppl):3-7.
40. Williamson L, Illingworth, Smith D, Mowat A. Oral quinine in ankylosing spondylitis: A randomized placebo controlled double blind crossover trial. J Rheumatol 2000;27:2054-5.
41. Brandt J, Buss B, Sieper J, Braun J. Efficacy of treatment with sulfasalazine versus azathioprine in ankylosing spondylitis. J Rheumatol 2000;27(suppl 59):55.
42. Durez P, Horsmans Y. Dramatic response after an intravenous loading dose of azathioprine in one case of severe and refractory ankylosing spondylitis. Rheumatology (Oxford) 2000;39:182-4.
43. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46:149-54.
44. Yamane K, Saito C, Natsuda H, Yuhara T, Akama T, Suzuki H, et al. Ankylosing spondylitis successfully treated with methotrexate. Intern Med 1993;32:53-6.
45. Biasi D, Carletto A, Caramaschi P, Pacor ML, Maleknia T, Bambara LM. Efficacy of methotrexate in the treatment of ankylosing spondylitis: A three-year open study. Clin Rheumatol 2000:19:114-17.
46. Roychaudhry B, Bintley-Bagot S, Hunt J, Turin EJ. Methotrexate in severe ankylosing spondylitis: A randomized placebo controlled, double-blind observer study [abstract]. Rheumatology (Oxford) 2001;40(suppl):43.
47. Keenan GF. Management of complications of glucocorticoid therapy. Clin Chest Med 1997;18:507-20.
48. Richter MB, Woo P, Panayi GS, Trull A, Unger A, Shepherd P. The effects of intravenous pulse methylprednisolone on immunological and inflammatory processes in ankylosing spondylitis. Clin Exp Immunol 1983;53:51-9.
49. Peters ND, Eistrup L. Intravenous methylprednisolone pulse therapy in ankylosing spondylitis. Scand J Rheumatol 1992;21:134-8.
50. Braun J, Bollow M, Seyrekbasan F, Haberle HJ, Eggens U, Mertz A, et al. Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: Clinical outcome and follow-up by dynamic magnetic resonance imaging. J Rheumatol 1996;23:659-64.
51. Bellamy N, Park W, Rooney PJ. What do we know about the sacroiliac joint? Semin Arthritis Rheum 1983;12:282-313.
52. Gunaydin I, Pereira PL, Daikeler T, Mohren M, Trubenbach J, Schick F, et al. Magnetic resonance imaging guided corticosteroid injection of the sacroiliac joints in patients with therapy resistant spondyloarthropathy: A pilot study. J Rheumatol 2000;27:424-8.
53. Maugars Y, Mathis C, Berthelot JM, Charlier C, Prost A. Assessment of the efficacy of sacroiliac corticosteroid injections in spondyloarthropathies: A double-blind study. Br J Rheumatol 1996;35:767-70.
54. Dunn CJ, Galinet LA, Wu H, Nugent FA, Schlachter ST, Staite ND, et al. Demonstration of novel anti-arthritic and anti-inflammatory effects of diphosphonates. J Pharmacol Exp Ther 1993;266:1691-8.
55. Russell RGG, Croucher PI, Rogers MJ. Biphosphonates: Pharmacology mechanisms of action and clinical uses. Osteoporos Int 1999:2(suppl):S66-80.
56. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomized trial of effect of alendronate on risk of fracture in fractures. Fracture Intervention Trial women with existing vertebral Research Group. Lancet 1996;348:1535-41.
57. Lipton A. Bisphosphonates and breast carcinoma: Present and future. Cancer 2000;88(suppl):3033-7.
58. Francis MD, Hovancik K, Boyce RW. NE-58095: A diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. Int J Tissue React 1989;11:239-52.
59. Flora L. Comparative antiinflammatory and bone protective effects of two diphosphonates in adjuvant arthritis. Arthritis Rheum 1979;22:340-6.
60. Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BA, Breedveld FC. Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: A double blind placebo controlled study. J Rheumatol 1994;21:2016-20.
61. Ralston SH, Hacking L, Willocks L, Bruce F, Pitkeathly DA. Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis 1989;48:396-9.
62. Maksymowych WP, Jhangri GS, Leclercq S, Skeith K, Yah A, Russell AS. An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol 1998;25:714-17.
63. Schweitzer DH, Oostendorp-van de Ruit M, van der Pluijm G, Lowik CW, Papapoulos SE. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 1995;10:956-62.
64. Maksymowych WP, Lambert R, Jhangri GS, Leclercq S, Chiu P, Wong B, et al. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol 2001;28:144-55.
65. Maksymowych WP, Jhangri GS, Fitzgerald AA, LeClercq S, Chiu P, Yan A, et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal anti-flammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002;46:766-73.
66. Adami S, Zamberlan N. Adverse effects of bisphosphonates. Drug Saf 1996;14:158-70.
67. Dagfinrud H, Hagen K. Physiotherapy interventions for ankylosing spondylitis (Cochrane review). Cochrane Database Syst Rev 2001;4:CD002822.
68. Hidding A, van der Linden S, Gielen X, de Witte L, Dijkmans B, Moolenburgh D. Continuation of group physical therapy is necessary in ankylosing spondylitis: Results of a randomized controlled trial. Arthritis Care Res 1994;7:90-6.
69. Helliwell PS, Abbott CA, Chamberlain MA. A randomised trial of three different physiotherapy regimens in ankylosing spondylitis. Physiotherapy 1996;82:85-90.
70. Kraag G, Stokes B, Groh J, Helewa A, Goldsmith C. The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis: A randomized controlled trial. J Rheumatol 1990;17:228-33.
71. van Tubergen A, Landewe R, van der Heijde D, Hidding A, Wolter N, Asscher M, et al. Combined spa-therapy is effective in patients with ankylosing spondylitis: A randomized controlled trial. Arthritis Rheum 2001;45:430-8.
72. van Tubergen A, Boonen, A, Landewé R, Rutten-van Mölken M, van der Heijde D, Hidding A, et al. Cost-effectiveness of combined spa-exercise therapy in ankylosing spondylitis: A randomized controlled trial. Arthritis Rheum (in press).
73. Fox MW, Onofrio BM, Kilgore JE. Neurological complications of ankylosing spondylitis. J Neurosurg 1993;78:871-8.
74. Ramos-Remus C, Gomez-Vargas A, Hernandez-Chavez A, Gamez-Nava JI, Bnozalez-Lopez L, Russell AS. Two year follow-up of anterior and vertical atlantoaxial subluxation in ankylosing spondylitis. J Rheumatol 1997;24:507-10.
75. Van Royen BJ, De Gast A. Lumbar osteotomy for correction of thoracolumbar kyphotic deformity in ankylosing spondylitis. A structured review of three methods of treatment. Ann Rheum Dis 1999;58:399-406.
76. Sweeney S, Gupta R, Taylor G, Calin A. Total hip arthroplasty in ankylosing spondylitis: Outcome in 340 patients. J Rheumatol 2001;28:1862-6.